Longeveron, Inc. (LGVN)
0.7706
0.00 (0.00%)
USD |
NASDAQ |
Jun 10, 16:00
0.7706
0.00 (0.00%)
After-Hours: 20:00
Longeveron SG&A Expense (Quarterly) : 2.72M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 2.72M |
| December 31, 2025 | 2.936M |
| September 30, 2025 | 3.583M |
| June 30, 2025 | 2.589M |
| March 31, 2025 | 2.941M |
| December 31, 2024 | 2.822M |
| September 30, 2024 | 3.125M |
| June 30, 2024 | 2.122M |
| March 31, 2024 | 2.20M |
| December 31, 2023 | 3.282M |
| September 30, 2023 | 3.372M |
| June 30, 2023 | 3.518M |
| Date | Value |
|---|---|
| March 31, 2023 | 2.012M |
| December 31, 2022 | 1.922M |
| September 30, 2022 | 2.319M |
| June 30, 2022 | 2.661M |
| March 31, 2022 | 2.267M |
| December 31, 2021 | 2.368M |
| September 30, 2021 | 3.021M |
| June 30, 2021 | 3.31M |
| March 31, 2021 | 2.257M |
| December 31, 2020 | 0.7605M |
| September 30, 2020 | 0.746M |
| December 31, 2019 | 0.7387M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| HCW Biologics Inc. | 1.833M |
| Arrowhead Pharmaceuticals, Inc. | 41.74M |
| Oncolytics Biotech, Inc. | 4.729M |
| Sangamo Therapeutics, Inc. | 6.818M |
| Sarepta Therapeutics, Inc. | 108.95M |